Intensity Therapeutics, Inc. (INTS)

NCM – Real Time Price. Currency in USD

4.88

-0.12 (-2.40%)

At close: May 12, 2026, 4:00 PM EDT

4.82

-0.06 (-1.23%)

After-hours: May 12, 2026, 6:57 PM EDT

07.05.2026

Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Cash and cash equivalents of $10.2 million as of March 31, 2026 Favorable efficacy and safety reported in a small sample of triple negative breast cancer ("TNBC") patients receiving INT230-6 prior to the standard of care ("SOC") compared to SOC alone in the INVINCIBLE-4 Study (as defined below) Approval to resume enrollment obtained in the INVINCIBLE-4 Study; plans to resume enrollment in the second quarter of 2026 Decision to resume enrollment in a limited number of U.S. sites in the INVINCIBLE-3 Study (as defined below) by the third quarter of 2026 SHELTON, Conn., May 7, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology, announces first quarter 2026 financial results and provides a corporate update.

01.05.2026

Intensity Therapeutics Inc. (INTS) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Intensity Therapeutics Inc. (INTS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

16.04.2026

Intensity Therapeutics Inc. (INTS) Upgraded to Buy: Here's What You Should Know

Intensity Therapeutics Inc. (INTS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

15.04.2026

Intensity Therapeutics Recognized with Pinnacle Award for Excellence in Healthcare Innovation

Company receives the Platinum Award for Innovator in Biotech Solutions Category SHELTON, Conn., April 15, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc., (Nasdaq: INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary cancer therapies using its non-covalent, drug-conjugation technology that creates drug products designed to kill tumors and increase immune system recognition of cancers, announces it has been named a winner of the 2026 Pinnacle Awards for Healthcare for its intratumoral injection platform and lead drug candidate INT230-6.

27.03.2026

Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update

Raised over $20 million in gross proceeds in 2025 and held $11.9 million in cash and cash equivalents as of December 31, 2025, with a cash runway into the second quarter of 2027 IT-01 Study manuscript of INT230-6 used alone in 64 refractory metastatic cancer patients published in the Lancet's journal eBioMedicine, including data for disease control rate, overall survival, immune activation, abscopal effects, tumor necrosis, dose ranging, and safety Favorable efficacy and safety reported in a small sample of triple negative breast cancer ("TNBC") patients receiving INT230-6 prior to the standard of care ("SOC") compared to SOC alone in the INVINCIBLE-4 Study SHELTON, Conn., March 27, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology, announces 2025 year-end financial results and highlights, and provides a corporate update.

24.03.2026

Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US

New US patent 12,496,345 strengthens the existing portfolio Patents now granted in 41 countries protect the Company's novel intratumoral technology, including lead compound INT230-6 SHELTON, Conn., March 24, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc., (Nasdaq: INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary cancer therapies using its non-covalent, drug-conjugation technology that creates drug products designed to kill tumors and increase immune system recognition of cancers, provided an update on its patent portfolio including the recent issuance in December 2025 of a new US patent in the U.S., US Patent Number 12,496,345, entitled "A Method of Treating Cancer".

12.03.2026

Intensity Therapeutics Updates Breast Cancer Trial, Files To Resume Enrollment Following Study Pause

Intensity Therapeutics Inc. (NASDAQ: INTS) on Thursday provided an update on the INVINCIBLE-4 Study.

Videos

No Data

There is no data to display

Press releases

07.05.2026

Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

15.04.2026

Intensity Therapeutics Recognized with Pinnacle Award for Excellence in Healthcare Innovation

27.03.2026

Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update

24.03.2026

Intensity Therapeutics, Inc. (INTS)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Intensity Therapeutics, Inc. (INTS)

Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Intensity Therapeutics Inc. (INTS) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Intensity Therapeutics Inc. (INTS) Upgraded to Buy: Here's What You Should Know

Intensity Therapeutics Recognized with Pinnacle Award for Excellence in Healthcare Innovation

Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update

Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US

Intensity Therapeutics Updates Breast Cancer Trial, Files To Resume Enrollment Following Study Pause

Videos

No Data

Press releases

Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Intensity Therapeutics Recognized with Pinnacle Award for Excellence in Healthcare Innovation

Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update

Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US

Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Intensity Therapeutics Inc. (INTS) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Intensity Therapeutics Inc. (INTS) Upgraded to Buy: Here's What You Should Know

Intensity Therapeutics Recognized with Pinnacle Award for Excellence in Healthcare Innovation

Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update

Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US

Intensity Therapeutics Updates Breast Cancer Trial, Files To Resume Enrollment Following Study Pause

Videos

No Data

Press releases

Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Intensity Therapeutics Recognized with Pinnacle Award for Excellence in Healthcare Innovation

Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update

Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US

Search stocks

Intensity Therapeutics, Inc. (INTS)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Intensity Therapeutics, Inc. (INTS)

Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Intensity Therapeutics Inc. (INTS) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Intensity Therapeutics Inc. (INTS) Upgraded to Buy: Here's What You Should Know

Intensity Therapeutics Recognized with Pinnacle Award for Excellence in Healthcare Innovation

Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update

Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US

Intensity Therapeutics Updates Breast Cancer Trial, Files To Resume Enrollment Following Study Pause

Videos

No Data

Press releases

Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Intensity Therapeutics Recognized with Pinnacle Award for Excellence in Healthcare Innovation

Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update

Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US

Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Intensity Therapeutics Inc. (INTS) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Intensity Therapeutics Inc. (INTS) Upgraded to Buy: Here's What You Should Know

Intensity Therapeutics Recognized with Pinnacle Award for Excellence in Healthcare Innovation

Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update

Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US

Intensity Therapeutics Updates Breast Cancer Trial, Files To Resume Enrollment Following Study Pause

Videos

No Data

Press releases

Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Intensity Therapeutics Recognized with Pinnacle Award for Excellence in Healthcare Innovation

Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update

Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US